Swiss drugmaker Vifor Pharma is aiming to complete more acquisitions or licensing deals this year, Chief Executive Stefan Schulze told Reuters. ZURICH, March 3 (Reuters) - Swiss drugmaker Vifor ...

CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd- Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021- Expands CSL's leadership across an ...

BRUSSELS, April 19 (Reuters) - Vifor Pharma has offered to launch a marketing campaign to address any damage caused by its criticisms of a rival to its key drug, EU regulators said on Friday ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject ® / Injectafer ® with sales up ...

It is a natural fit to our leading product portfolio in nephrology, and we look forward to making it available to patients who urgently need better therapy,” said Stefan Schulze, Vifor Pharma ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track.

(RTTNews) - Under a settlement agreement of Injectafer patent litigation, Vifor Pharma (GNHAF.OB) and American Regent will grant Mylan Laboratories Ltd., and Sandoz, Inc., licenses to market ...

Vifor Pharma is losing a chief commercial officer but gaining a new chief medical officer in the form of Sanofi’s Klaus Henning Jensen. Jensen joins from the French Big Pharma where he was its ...

Following the IPO, Galenica Group becomes Vifor Pharma Group and will be listed on the Swiss Stock Exchange under its new ticker, VIFN. The company has thus taken the final steps toward separating ...